If You Invested in ZYVERSA THERAPEUTICS INC (ZVSA)

ZyVersa Therapeutics, Inc. (symbol ZVSA) is a clinical-stage specialty biopharmaceutical company focused on developing first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. According to multiple company disclosures, ZyVersa is advancing a therapeutic development pipeline built around two proprietary technology platforms: Cholesterol Efflux Mediator™ VAR 200 for kidney diseases and Inflammasome ASC Inhibitor IC 100 for chronic inflammatory and cardiometabolic conditions.

Core therapeutic platforms

The company states that its pipeline is organized around two globally licensed development platforms discovered by research scientists at the University of Miami Miller School of Medicine. In its registration statement, ZyVersa describes:

• Cholesterol Efflux Mediator™ VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) – an injectable drug in phase 2 development intended to ameliorate renal lipid accumulation that damages the kidneys’ filtration system and contributes to the development and progression of kidney disease. Company materials report that VAR 200 removes excess lipids from the kidney both passively and actively by upregulating cholesterol efflux transporters ABCA1 and ABCG1.
• Inflammasome ASC Inhibitor IC 100 – a humanized monoclonal antibody in preclinical development targeting the ASC component of inflammasomes. ZyVersa describes IC 100 as designed to inhibit damaging inflammation associated with numerous central nervous system (CNS) and peripheral inflammatory diseases, with a lead focus on obesity with cardiometabolic comorbidities and other cardiometabolic conditions.

Renal disease focus and VAR 200

ZyVersa’s disclosures emphasize a strategic focus on chronic glomerular kidney diseases. The company identifies focal segmental glomerulosclerosis (FSGS) as the lead indication for VAR 200, with potential indication expansion into Alport syndrome and diabetic kidney disease (DKD). Company press releases and SEC filings explain that VAR 200 is being developed to address renal lipotoxicity – excess accumulation of cholesterol and other lipids in the glomerulus and kidney filtration system, which is associated with inflammation, fibrosis, oxidative stress, endoplasmic reticulum stress, and progressive kidney damage.

According to ZyVersa’s public communications, preclinical studies of VAR 200 in animal models of FSGS, Alport syndrome, and DKD have demonstrated:

• Reduced levels of cholesterol and other lipids in kidney tissues
• Protection against renal injury and fibrosis
• Improvement in proteinuria (reduction in protein leakage into the urine)

The company reports that an open-label phase 2a clinical trial in patients with diabetic kidney disease has been initiated to obtain patient proof-of-concept before a larger phase 2a/b trial in FSGS. ZyVersa also notes that VAR 200 is being used under FDA-authorized Emergency Compassionate Use in a patient with ApoCII amyloidosis, an ultra-rare kidney-dominant disease, following a protocol aligned with its DKD trial.

Inflammatory and cardiometabolic disease focus and IC 100

ZyVersa’s second platform, Inflammasome ASC Inhibitor IC 100, targets chronic inflammatory pathways. Company communications describe IC 100 as an inflammasome inhibitor that binds the ASC adaptor component rather than a single inflammasome sensor such as NLRP3. ZyVersa states that by targeting ASC and associated ASC specks, IC 100 is intended to inhibit multiple types of inflammasomes and to attenuate both initiation and propagation of inflammation.

In its news releases, ZyVersa highlights preclinical data in cardiometabolic and inflammatory models, including:

• Decreased insulin resistance in a diabetic kidney disease model, based on reduced fasting glucose
• Reduced inflammation and plaque in the aorta in an atherosclerosis model
• Reduced cardiac inflammation and attenuation of cardiac dysfunction in a stroke-related cardiovascular disease model

The company identifies obesity with cardiometabolic comorbidities as the lead indication for IC 100 and has discussed plans for IND-enabling preclinical studies in a diet-induced obesity model, with the goal of progressing to a phase 1 trial in overweight subjects at risk for cardiometabolic conditions. ZyVersa also references preclinical work in neurological disease models, including Parkinson’s disease, in its shareholder communications.

Business model and development stage

In its registration statement and press releases, ZyVersa characterizes itself as a clinical-stage biopharmaceutical company that is leveraging proprietary technologies to develop drug candidates rather than marketing approved products. The company’s stated mission is to develop therapies that optimize health outcomes and improve quality of life for patients with serious renal and inflammatory conditions. ZyVersa’s disclosures focus on:

• Advancing VAR 200 through clinical proof-of-concept in DKD and FSGS, with potential indication expansion to other kidney diseases characterized by renal lipotoxicity
• Completing preclinical development and initiating first-in-human studies for IC 100 in obesity with cardiometabolic complications and other inflammatory indications
• Obtaining the financing required to support ongoing research and development, clinical trials, and general operations

The company notes in its financial reports that it generates losses associated with research and development and general and administrative expenses, and that it expects to seek funding through equity, debt, and other financing arrangements, as well as potential grants or collaborations.

Regulatory and listing status

According to SEC filings, ZyVersa’s common stock was previously listed on The Nasdaq Capital Market under the symbol ZVSA. An 8-K dated September 14, 2025, and a Form 25 filed on October 6, 2025, report that Nasdaq initiated the delisting of the company’s common stock under Exchange Act Rule 12d2-2. The filings state that trading on Nasdaq was suspended on July 17, 2025, and that the company’s common stock has been quoted on the OTCQB Venture Market under the symbol ZVSA. The Form 25 identifies Nasdaq Stock Market LLC as the exchange from which the security was removed from listing and registration. ZyVersa’s subsequent filings and press releases continue to reference trading on the OTCQB.

Capital markets and financing activities

ZyVersa’s SEC filings describe several capital markets transactions intended to fund its development programs. These include:

• An Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, giving ZyVersa the right to sell up to a specified investment amount of common stock over a defined term, with associated registration rights and commitment shares.
• A warrant exercise inducement transaction in which an institutional investor agreed to exercise existing warrants at a reduced exercise price in exchange for new Series A-4 warrants, generating gross proceeds that the company states are intended for working capital and general corporate purposes.
• A registration statement on Form S-1 relating to the resale of shares issued or issuable under the equity purchase arrangement with Williamsburg.

The company’s quarterly financial statements and related 8-K filings highlight that ZyVersa has experienced recurring net losses and reports that it expects its cash and cash equivalents to fund operations on a month-to-month basis, with a stated need for additional financing to support continuing operations and pipeline development.

Geographic base and sector classification

SEC filings list ZyVersa’s principal executive offices as being located in Weston, Florida, and identify the company as operating in the biopharmaceutical and biotechnology research and development domain. In the industry classification provided, ZyVersa is associated with research and development in biotechnology within the broader professional, scientific, and technical services sector.

Investment and research considerations

For investors and researchers evaluating ZVSA stock, ZyVersa’s public disclosures underscore several key points:

• The company is clinical-stage, with no approved commercial products described in the provided materials.
• Its value proposition centers on two proprietary platforms targeting renal lipotoxicity (VAR 200) and inflammasome-mediated inflammation (IC 100).
• The company’s common stock has been delisted from Nasdaq and is quoted on the OTCQB Venture Market, as documented in Form 8-K and Form 25 filings.
• Ongoing operations depend on the company’s ability to obtain additional capital, as discussed in its financial result announcements and SEC filings.

All of these elements are drawn from ZyVersa’s own press releases, financial reports, and SEC filings, which together provide a picture of a small, development-stage biopharmaceutical company focused on kidney and inflammatory diseases, with active clinical and preclinical programs and a reliance on external financing.